Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Express Scripts
Daiichi Sankyo
US Army
Argus Health

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,092,525

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,092,525
Title:Use of cannabinoids in the treatment of epilepsy
Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s): Guy; Geoffrey (London, GB), Wright; Stephen (London, GB), Mead; Alice (Cambridge, GB), Devinsky; Orrin (New York, NY)
Assignee: GW Pharma Limited (Vision Park, Histon, Cambridge, GB)
Application Number:15/449,402
Patent Claims: 1. A method of reducing drop seizure frequency in a patient with Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) .DELTA.9-tetrahydrocannabinol (THC), and wherein the dose of the CBD is about 20 mg/kg/day.

2. The method of claim 1, wherein the CBD comprises .DELTA.9-tetrahydrocannabinol (THC).

3. The method of claim 1, wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED) to the subject in need thereof at a recommended therapeutic dose of the AED.

4. The method of claim 3, wherein the one or more AED is selected from the group consisting of: clobazam; clonazepam, levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin.

5. A method of treating drop seizures in a patient with Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the purity of the CBD is at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) .DELTA.9-tetrahydrocannabinol (THC), and where the dose of the CBD is about 20 mg/kg/day.

6. The method of claim 5, wherein the CBD comprises .DELTA.9-tetrahydrocannabinol (THC).

7. The method of claim 5, wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED) to the subject in need thereof at a recommended therapeutic dose of the AED.

8. The method of claim 7, wherein the one or more AED is selected from the group consisting of: clobazam; clonazepam, levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Chubb
Medtronic
Fuji
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.